Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Lenvantinib + Everolimus
f. Nivolumab
g. Nivolumab + Ipilimumab
h. Pazopanib
i. Pembrolizumab + Axitinib
j. Sunitinib
k. Temsirolimus
l. Tivozanib
m. Other
Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib + Trametinib
d. Encorafenib + Binimetinib
e. Ipilimumab
f. Ipilimumab + Nivolumab
g. Nivolumab
h. Pembrolizumab
i. Trametinib
j. Vemurafenib
k. Vemurafenib + Cobimetinib
l. Other active systemic anti-cancer therapy
m. Palliative care only
3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib + Trametinib
d. Encorafenib + Binimetinib
e. Ipilimumab
f. Ipilimumab + Nivolumab
g. Nivolumab
h. Pembrolizumab
i. Trametinib
j. Vemurafenib
k. Vemurafenib + Cobimetinib
l. Other active systemic anti-cancer therapy
m. Palliative care only
